Research ArticleHematologyVascular biology Free access | 10.1172/jci.insight.120451
1Laboratory of Biochemistry and Vascular Biology and
2Laboratory of Cellular Hematology, Division of Blood Components and Devices, Center for Biologics Evaluation and Research, FDA, Silver Spring, Maryland, USA.
3Vulcan Analytical LLC, Birmingham, Alabama, USA.
4Division of Hematology, Oncology and Transplantation, University of Minnesota Medical School, Minneapolis, Minnesota, USA.
Address correspondence to: Abdu I. Alayash, Laboratory of Biochemistry and Vascular Biology, Center for Biologics Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Avenue, Building 52/72, Room 4106, Silver Spring, Maryland 20993, USA. Phone: 240.402.9350; Email: abdu.alayash@fda.hhs.gov.
Authorship note: SJ and MBS contributed equally to this work.
Find articles by Jana, S. in: JCI | PubMed | Google Scholar
1Laboratory of Biochemistry and Vascular Biology and
2Laboratory of Cellular Hematology, Division of Blood Components and Devices, Center for Biologics Evaluation and Research, FDA, Silver Spring, Maryland, USA.
3Vulcan Analytical LLC, Birmingham, Alabama, USA.
4Division of Hematology, Oncology and Transplantation, University of Minnesota Medical School, Minneapolis, Minnesota, USA.
Address correspondence to: Abdu I. Alayash, Laboratory of Biochemistry and Vascular Biology, Center for Biologics Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Avenue, Building 52/72, Room 4106, Silver Spring, Maryland 20993, USA. Phone: 240.402.9350; Email: abdu.alayash@fda.hhs.gov.
Authorship note: SJ and MBS contributed equally to this work.
Find articles by Strader, M. in: JCI | PubMed | Google Scholar
1Laboratory of Biochemistry and Vascular Biology and
2Laboratory of Cellular Hematology, Division of Blood Components and Devices, Center for Biologics Evaluation and Research, FDA, Silver Spring, Maryland, USA.
3Vulcan Analytical LLC, Birmingham, Alabama, USA.
4Division of Hematology, Oncology and Transplantation, University of Minnesota Medical School, Minneapolis, Minnesota, USA.
Address correspondence to: Abdu I. Alayash, Laboratory of Biochemistry and Vascular Biology, Center for Biologics Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Avenue, Building 52/72, Room 4106, Silver Spring, Maryland 20993, USA. Phone: 240.402.9350; Email: abdu.alayash@fda.hhs.gov.
Authorship note: SJ and MBS contributed equally to this work.
Find articles by Meng, F. in: JCI | PubMed | Google Scholar
1Laboratory of Biochemistry and Vascular Biology and
2Laboratory of Cellular Hematology, Division of Blood Components and Devices, Center for Biologics Evaluation and Research, FDA, Silver Spring, Maryland, USA.
3Vulcan Analytical LLC, Birmingham, Alabama, USA.
4Division of Hematology, Oncology and Transplantation, University of Minnesota Medical School, Minneapolis, Minnesota, USA.
Address correspondence to: Abdu I. Alayash, Laboratory of Biochemistry and Vascular Biology, Center for Biologics Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Avenue, Building 52/72, Room 4106, Silver Spring, Maryland 20993, USA. Phone: 240.402.9350; Email: abdu.alayash@fda.hhs.gov.
Authorship note: SJ and MBS contributed equally to this work.
Find articles by Hicks, W. in: JCI | PubMed | Google Scholar
1Laboratory of Biochemistry and Vascular Biology and
2Laboratory of Cellular Hematology, Division of Blood Components and Devices, Center for Biologics Evaluation and Research, FDA, Silver Spring, Maryland, USA.
3Vulcan Analytical LLC, Birmingham, Alabama, USA.
4Division of Hematology, Oncology and Transplantation, University of Minnesota Medical School, Minneapolis, Minnesota, USA.
Address correspondence to: Abdu I. Alayash, Laboratory of Biochemistry and Vascular Biology, Center for Biologics Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Avenue, Building 52/72, Room 4106, Silver Spring, Maryland 20993, USA. Phone: 240.402.9350; Email: abdu.alayash@fda.hhs.gov.
Authorship note: SJ and MBS contributed equally to this work.
Find articles by Kassa, T. in: JCI | PubMed | Google Scholar
1Laboratory of Biochemistry and Vascular Biology and
2Laboratory of Cellular Hematology, Division of Blood Components and Devices, Center for Biologics Evaluation and Research, FDA, Silver Spring, Maryland, USA.
3Vulcan Analytical LLC, Birmingham, Alabama, USA.
4Division of Hematology, Oncology and Transplantation, University of Minnesota Medical School, Minneapolis, Minnesota, USA.
Address correspondence to: Abdu I. Alayash, Laboratory of Biochemistry and Vascular Biology, Center for Biologics Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Avenue, Building 52/72, Room 4106, Silver Spring, Maryland 20993, USA. Phone: 240.402.9350; Email: abdu.alayash@fda.hhs.gov.
Authorship note: SJ and MBS contributed equally to this work.
Find articles by Tarandovskiy, I. in: JCI | PubMed | Google Scholar
1Laboratory of Biochemistry and Vascular Biology and
2Laboratory of Cellular Hematology, Division of Blood Components and Devices, Center for Biologics Evaluation and Research, FDA, Silver Spring, Maryland, USA.
3Vulcan Analytical LLC, Birmingham, Alabama, USA.
4Division of Hematology, Oncology and Transplantation, University of Minnesota Medical School, Minneapolis, Minnesota, USA.
Address correspondence to: Abdu I. Alayash, Laboratory of Biochemistry and Vascular Biology, Center for Biologics Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Avenue, Building 52/72, Room 4106, Silver Spring, Maryland 20993, USA. Phone: 240.402.9350; Email: abdu.alayash@fda.hhs.gov.
Authorship note: SJ and MBS contributed equally to this work.
Find articles by De Paoli, S. in: JCI | PubMed | Google Scholar
1Laboratory of Biochemistry and Vascular Biology and
2Laboratory of Cellular Hematology, Division of Blood Components and Devices, Center for Biologics Evaluation and Research, FDA, Silver Spring, Maryland, USA.
3Vulcan Analytical LLC, Birmingham, Alabama, USA.
4Division of Hematology, Oncology and Transplantation, University of Minnesota Medical School, Minneapolis, Minnesota, USA.
Address correspondence to: Abdu I. Alayash, Laboratory of Biochemistry and Vascular Biology, Center for Biologics Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Avenue, Building 52/72, Room 4106, Silver Spring, Maryland 20993, USA. Phone: 240.402.9350; Email: abdu.alayash@fda.hhs.gov.
Authorship note: SJ and MBS contributed equally to this work.
Find articles by Simak, J. in: JCI | PubMed | Google Scholar
1Laboratory of Biochemistry and Vascular Biology and
2Laboratory of Cellular Hematology, Division of Blood Components and Devices, Center for Biologics Evaluation and Research, FDA, Silver Spring, Maryland, USA.
3Vulcan Analytical LLC, Birmingham, Alabama, USA.
4Division of Hematology, Oncology and Transplantation, University of Minnesota Medical School, Minneapolis, Minnesota, USA.
Address correspondence to: Abdu I. Alayash, Laboratory of Biochemistry and Vascular Biology, Center for Biologics Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Avenue, Building 52/72, Room 4106, Silver Spring, Maryland 20993, USA. Phone: 240.402.9350; Email: abdu.alayash@fda.hhs.gov.
Authorship note: SJ and MBS contributed equally to this work.
Find articles by Heaven, M. in: JCI | PubMed | Google Scholar |
1Laboratory of Biochemistry and Vascular Biology and
2Laboratory of Cellular Hematology, Division of Blood Components and Devices, Center for Biologics Evaluation and Research, FDA, Silver Spring, Maryland, USA.
3Vulcan Analytical LLC, Birmingham, Alabama, USA.
4Division of Hematology, Oncology and Transplantation, University of Minnesota Medical School, Minneapolis, Minnesota, USA.
Address correspondence to: Abdu I. Alayash, Laboratory of Biochemistry and Vascular Biology, Center for Biologics Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Avenue, Building 52/72, Room 4106, Silver Spring, Maryland 20993, USA. Phone: 240.402.9350; Email: abdu.alayash@fda.hhs.gov.
Authorship note: SJ and MBS contributed equally to this work.
Find articles by Belcher, J. in: JCI | PubMed | Google Scholar |
1Laboratory of Biochemistry and Vascular Biology and
2Laboratory of Cellular Hematology, Division of Blood Components and Devices, Center for Biologics Evaluation and Research, FDA, Silver Spring, Maryland, USA.
3Vulcan Analytical LLC, Birmingham, Alabama, USA.
4Division of Hematology, Oncology and Transplantation, University of Minnesota Medical School, Minneapolis, Minnesota, USA.
Address correspondence to: Abdu I. Alayash, Laboratory of Biochemistry and Vascular Biology, Center for Biologics Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Avenue, Building 52/72, Room 4106, Silver Spring, Maryland 20993, USA. Phone: 240.402.9350; Email: abdu.alayash@fda.hhs.gov.
Authorship note: SJ and MBS contributed equally to this work.
Find articles by Vercellotti, G. in: JCI | PubMed | Google Scholar
1Laboratory of Biochemistry and Vascular Biology and
2Laboratory of Cellular Hematology, Division of Blood Components and Devices, Center for Biologics Evaluation and Research, FDA, Silver Spring, Maryland, USA.
3Vulcan Analytical LLC, Birmingham, Alabama, USA.
4Division of Hematology, Oncology and Transplantation, University of Minnesota Medical School, Minneapolis, Minnesota, USA.
Address correspondence to: Abdu I. Alayash, Laboratory of Biochemistry and Vascular Biology, Center for Biologics Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Avenue, Building 52/72, Room 4106, Silver Spring, Maryland 20993, USA. Phone: 240.402.9350; Email: abdu.alayash@fda.hhs.gov.
Authorship note: SJ and MBS contributed equally to this work.
Find articles by Alayash, A. in: JCI | PubMed | Google Scholar
Authorship note: SJ and MBS contributed equally to this work.
Published November 2, 2018 - More info
The contribution of intracellular hemoglobin (Hb) oxidation to RBC-derived microparticle (MP) formation is poorly defined in sickle cell disease (SCD). Here we report that sickle Hb (HbS) oxidation, coupled with changes in cytosolic antioxidative proteins, is associated with membrane alterations and MP formation in homozygous Townes–sickle cell (Townes-SS) mice. Photometric and proteomic analyses confirmed the presence of high levels of Hb oxidation intermediates (ferric/ferryl) and consequent β-globin posttranslational modifications, including the irreversible oxidation of βCys93 and the ubiquitination of βLys96 and βLys145. This is the first report to our knowledge to link the UPS (via ubiquitinated Hb and other proteins) to oxidative stress. Ferryl Hb also induced complex formation with band 3 and RBC membrane proteins. Incubation of Townes-SS MPs with human endothelial cells caused greater loss of monolayer integrity, apoptotic activation, heme oxygenase-1 induction, and concomitant bioenergetic imbalance compared with control Townes-AA MPs. MPs obtained from Townes-SS mice treated with hydroxyurea produced fewer posttranslational Hb modifications. In vitro, hydroxyurea reduced the levels of ferryl Hb and shielded its target residue, βCys93, by a process of S-nitrosylation. These mechanistic analyses suggest potential antioxidative therapeutic modalities that may interrupt MP heme-mediated pathophysiology in SCD patients.
Sickle cell disease (SCD) is characterized by chronic hemolysis, intermittent vaso-occlusive crises, and organ damage (1). Hemolysis results in the release of RBC-derived microparticles (MPs) and hemoglobin (Hb) in circulation. It has previously been reported that heme released (approximately 25 μM) during a sickling crisis (originating from these 2 sources) may contribute to the complications of blood vessel injury and inflammation (2, 3). Several molecular mechanisms that contribute to a high oxidative burden in SCD patients have been proposed in recent years (4). Oxidative stress is increased in SCD and likely plays a significant role in the pathophysiology of SCD-related microvascular dysfunction, vaso-occlusion, and development of organ damage (5, 6). NADPH oxidase–derived ROS reported in sickle RBCs may also cause direct oxidative damage to a variety of subcellular structures, leading to a reduction in deformability that consequently increases RBC fragility and hemolysis (6, 7).
A number of recent preclinical models have provided considerable support to the notion that cell-free Hb (infused and/or released from outdated blood in normal or diseased animals) plays a significant role in the development of oxidative toxicity (8–10). In one report, oxidized HbFe3+ (metHb) or free heme was shown to trigger vaso-occlusion in SCD (but not in normal WT control) mice. The fact that metHb (but not cyanometHb, in which the iron is blocked by cyanide) induced vaso-occlusion indicated that heme liberation was necessary. In the same study, Hb-induced vaso-occlusion was blocked by the metHb-reducing agent methylene blue, haptoglobin (Hp), and the heme-binding protein hemopexin (HPX) (8). Heme (released from Hb), now recognized by many as a damage-associated molecular pattern (DAMP) molecule, was shown to elicit vaso-occlusion (stasis) and acute chest syndrome in transgenic sickle mice by binding to endothelial TLR4 (8, 11).
The unique oxidative environment (within sickle cell RBCs [SS RBCs]) acts as an incubator for oxidized Hb redox forms (12). Because of the catalytic nature of these oxidation reactions, Hb is proposed to participate (inside and outside RBCs) in pseudoenzymatic radical side reactions (12). Moreover, we have recently reported that free sickle Hb (HbS) oxidizes faster, remains locked in a highly oxidizing ferryl state (HbFe4+) longer, and loses its heme more rapidly than HbA. In the same report, we also found that the persistent ferryl HbS (and its associated protein radicals) was responsible for irreversibly oxidizing Hb specific “hotspot” amino acids including βCys93, as well as targeting subcellular organelles such as the mitochondria (13).
Several MP subtypes have been observed in SCD blood, namely those derived from RBCs, platelets, endothelial cells, and monocytes. MPs increase in number as they bud from RBCs after cycles of sickling/unsickling (14, 15). MPs are submicron, unilamellar vesicles possessing a lipid bilayer and proteins derived from the plasma membrane of their parent cells of origin. RBC-derived MPs (isolated from the plasma of freshly drawn blood) have been shown to contain all Hb components in a pattern like that of parent RBCs (14). Approximately 20%–30% of the RBC-derived MP content consists of Hb; however, these vesicles also contain enzymes, microRNA (miRNA), and other multifunctional biologic mediators (15). In transgenic SCD mice, infusion of heme-laden MPs has been shown to trigger rapid vaso-occlusion in kidneys and compromise microvascular dilation ex vivo (16). These vascular effects were largely blocked for both in vitro and in vivo conditions by the heme-scavenging protein HPX and by the PS antagonist annexin V (3). This suggests that Hb oxidative pathways (which lead to heme loss) are likely occurring within circulating particles. There is therefore a need for the basic understanding of the molecular events (inside RBCs/MPs) that ultimately lead to Hb/heme loss to the circulation and their effect on the vascular system.
In this study, we monitored the kinetics of Hb oxidation as well as changes in the proteomic landscape of transgenic sickle (Townes-SS) mouse RBC-derived MPs. Specifically, this study focused on Hb pseudoperoxidative activity, which is responsible for driving RBC cytosolic and membrane changes and promoting oxidative toxicity toward the vascular system. We also compared the toxicities of RBC-derived MPs from Townes-SS mice with those from control Townes-AA mice on cultured human umbilical vein endothelial cells (HUVECs). Finally, we have revealed that MPs from Townes-SS mice treated with hydroxyurea (HU; one of 2 FDA–approved drugs for the treatment of SCD patients) reversed many oxidative changes within these vesicles. Interestingly, a newly approved l-glutamine has been shown to have antioxidant properties (17).
Electrophoretic confirmation of SCD and the characterization of red cell–derived MPs from sickle cell mice. Electrophoretic mobility of hemolysates obtained from homozygous (SS), heterozygous (AS), and normal control (AA) Townes mice were carried out using isoelectric focusing to confirm the phenotype of blood samples derived from each animal (data not shown). RBC-derived MPs were then generated by shear stress from RBCs of Townes-AA or -SS mouse blood using a hypodermic syringe. The method used in this study was adopted with some modification from a previously published method using a cell disruptor (18), thus mimicking physiological fluid-shear stress that occurs within vessels during circulation. MP vesicular structure was confirmed by transmission electron microcopy (TEM). TEM images of MPs isolated from Townes-AA and -SS mouse RBCs are shown in Figure 1, A and B. Although an equal quantity of AA RBCs always had a lower yield of MPs compared with SS RBCs, AA and SS MPs appeared very similar under the TEM. Most MPs appeared as dense lipid vesicular structures between 100 and 300 nm in size. However, a few smaller MPs (~80 nm) and larger vesicles (>300 nm) were also seen. Interestingly, some SS MPs also showed dense protein aggregates on the vesicular membrane and within the vesicles (Figure 1C). Flow cytometry was done using FITC-conjugated annexin V to count and confirm shear stress MPs (Figure 1D) bearing externalized phosphatidylserine (PS). Both AA and SS MPs showed a small variation in the number of PS-positive vesicles, ranging from 80% to 90% of the total population. For proteomic, biochemical, and spectroscopic analysis, MPs were compared after normalization to total protein content.
Characterization of RBC-derived microparticles from Townes mice. Representative transmission electron microscopic images showing Townes-AA (A) and Townes-SS RBC–derived (B and C) shear stress MPs of size ranging from 200 to 500 nm. Solid white arrows indicate dense protein aggregates within MPs. All images are representative of experiments repeated at least 3 times and obtained from different MP preparations. (D) Representative scatter plot shows quantification of PS+ MPs by flow cytometry using FITC-conjugated annexin V following calibration with standard silica beads. Scale bars: 500 nm (A); 200 nm (B and C).
Spectrophotometric and chromatographic analyses of MPs reveal heme iron oxidation and subunit changes in sickle cell Hb. To understand how RBCs’ internal Hb oxidation reactions contribute to heme loss and membrane alterations, we monitored the progression of these reactions continuously for an extended period of 36 hours at room temperature using highly specialized spectrophotometric methods. These incubation times were considerably longer than the half-life of plasma circulating MPs in vivo (14, 15). A typical UV-visible absorbance spectrum captured during autoxidation (spontaneous) of free HbA is shown in Figure 2A. Ferrous Hb (HbFe+2) (2 major peaks, at 541 and 577 nm) was slowly transformed into the ferric/met form (HbFe+3) (absorbs strongly at 630 nm). The progression of oxidation within MPs derived from Townes-SS blood is shown in Figure 2B. Similar spectral changes were observed in AA MP solutions due to the transformation of ferrous Hb in a classic pseudoperoxidative redox cycle to ferryl/ferric states. However, the initial oxidation rates for ferrous Hb were slightly faster in SS MP solutions (Kauto = 0.044 hours–1 vs. Kauto = 0.027 hours–1) and there was less metHb accumulated in SS MPs (35%) as compared with AA MPs (45%) after 36-hour incubation (data not shown). The highly reactive ferryl Hb (HbFe+4) intermediate (peaks at 545 and 584 nm and a flattened region between 600 and 650 nm) was apparent toward the end of the incubation period in both SS and, to lesser, extent AA MPs (data not shown for AA MPs). Ferryl Hb was also verified by adding sodium sulfide (Na2S) to convert it to sulfhemoglobin (sulfHb), which absorbs strongly at 418 and 620 nm, respectively. Due to solution turbidity and low levels of ferryl Hb in MPs, we monitored sulfHb formation in the Soret region (418 nm) (data not shown). These data strongly contrast with the cell-free HbA control, where minimal spectral changes were detected within the same time frame (Figure 2A).
Hemoglobin S within microparticles undergoes oxidation and oxidative changes. Kinetic absorbance spectra of HbA control (A) and RBC MPs prepared from Townes-SS mice (B) (note: ferryl Hb spectrum is recognized by 2 new peaks at 545 and 584 nm and a flattened region between 500 and 700 nm). The samples were incubated for the indicated times in PBS at 37°C. Reverse-phase HPLC analyses of RBC MPs (AA and SS) before and after 36 hours of incubation (autoxidation) (C). The flow rate was 1 ml/min at 25°C. The eluate was monitored at 280 nm (for globin chains) and 405 nm (for heme). (D) Time course kinetics of metHb formation during autoxidation of HbA and HbS inside MPs prepared from AA and SS mice compared with free HbA samples, as determined spectrophotometrically during the 30-hour incubation. (E) Carbonylated protein content and (F) total lipid hydroperoxide content were measured in RBC MPs (n = 4). Upper horizontal line in box plots represents 75th percentile, lower horizontal line represents 25th percentile, and horizontal line within box represents mean value. Vertical error bars represent 95% confidence interval. Student’s t test, 2-tailed, *P < 0.05.
When challenged with H2O2, free HbS undergoes oxidative changes in both α and β subunits that involve irreversible oxidation of βCys93 and formation of heme-protein adducts (19, 20). These structural changes can be identified by reverse-phase HPLC methods and can be used as diagnostic biomarkers of oxidative changes in the protein and in blood (21). HPLC analysis of HbS subunits within MPs showed considerable alterations in both the β and α subunits, likely due to the effects of ferryl Hb–mediated oxidative reactions (22). AA MP samples revealed little or no modification of either the β or α subunit (Figure 2C, top panel), which correlates well with the spectrophotometric HbA control data in Figure 2A. SS MP samples, however, showed a marked reduction in α- and βS-globin subunits (Figure 2C, bottom panel), consistent with the HbS oxidation shown in Figure 2B. Heme peaks in both samples remained constant for all runs, which was used as an internal control to evaluate changes seen within the protein as a function of time (Figure 2C, top and bottom panels). Biphasic time courses during Hb autoxidation within MPs were observed, with initial metHb levels of 30%–40%; the levels then slightly declined in the first approximately 10 hours (likely due to the activity of RBCs’ residual antioxidant enzymes within MPs), again reaching a maximum of 35%–40% of total Hb (Figure 2D). There was a significant difference in metHb levels between the start and end point of the time course (P = 0.044 for AA MPs vs. P = 0.005 for SS MPs), and there was also a significant difference between the start and 10-hour time point (P = 0.001 for AA MP vs. P = 0.020 for SS MP). Because of the presence of residual antioxidant enzymes (SOD and catalase) within MPs, the metHb levels inside these MPs were lower than that of free Hb (P = 0.001 for AA MP and P = 0.004 for SS MP). This is contrasted with the linear kinetics of metHb accumulation (up to 65%–75%) in the free HbA solutions. We also carried out initial assessments of oxidative modification markers in the MPs, e.g., protein carbonylation and lipid hydroperoxide formation. A significantly higher level of carbonylated proteins in RBC MPs was obtained from Townes-SS mice compared with AA controls (Figure 2E). However, we did not see any significant difference in lipid hydroperoxide level between the 2 groups of MPs (Figure 2F).
Changes in MP antioxidative proteins occur in parallel to Hb oxidation. We used a high-resolution accurate mass (HRAM) mass spectrometry (HRAM-MS) strategy to quantify proteomic changes within RBC MPs from AA and SS mouse samples at t = 0 and 30 hours. As shown in Figure 3A, a considerable reduction in the antioxidative enzyme/protein levels (glutathione peroxidase 1, peroxiredoxin 6, thioredoxin, catalase, SOD) in SS mice at 30 hours was observed, which largely correlated with the Hb oxidation kinetics shown in Figure 2D. The substantial reduction of these enzymes after 30 hours in SS mice suggests that these proteins were consumed in the process of counteracting the rising levels of Hb oxidation products including ferric/ferryl Hbs. This is consistent with reported redox imbalances and impairments in enzymes involved in antioxidant protection and elimination of H2O2 within SS RBCs (4, 23). Also, of note, the levels of antioxidant enzymes were higher in SS MPs compared with AA MPs at both time points which may reflect the fact that SS RBCs were experiencing more oxidative stress and consequently higher levels of oxidized Hb at t = 0 (Figure 2D).
Changes in antioxidative proteins parallel hemoglobin S oxidation in microparticles. (A) Individual plots represent mean ± SEM of relative abundance determined from summed ion current intensity values for each oxidative enzyme, representing AA and SS microparticles (n = 3) at 0- and 30-hour incubations (37°C); measurements were determined by peptide MS1 chromatogram intensities that were combined for each protein into protein-level data. (B and C) Volcano plots (0 and 30 hours) represent average relative fold differences determined by plotting P values (–log10) for each protein against the calculated fold change (log2) difference (of that protein) in SS MP relative to AA MP peptide MS1 chromatogram intensities that were combined for each protein into protein-level data. ub@ and phosphoserine@ refer to the posttranslational modifications ubiquitination and serine phosphorylation (at the specified amino acid position), respectively. All peptide-spectrum matches were obtained using a strict 1% protein FDR. P values were generated by applying a t test statistic to log2-transformed fold change values for each mouse biological condition. All points (for both volcano plots) on or above the horizontal line parallel to the x axis represent proteins with P values of 0.05 or lower. All points on or to the left of the first vertical line parallel to the y axis represent proteins that were downregulated in SS mice 1.5-fold or greater. All points on or to the right of the second vertical line parallel to the y axis represent proteins that were upregulated in SS mice 1.5-fold or greater. Bars represent average mean value; each dot in the bars represents an individual data point, and vertical error bars represent SEM. Student’s t test, 2-tailed, *P < 0.05 vs. corresponding AA 0-hour samples.
Hb undergoes posttranslational modification within MPs. A comprehensive proteomic comparison of AA and SS mouse MPs at t = 0 and t = 30 hours is shown in Figure 3, B and C — by proteome-wide quantification volcano plots consisting of P values (–log10) of each protein versus fold change (log2) difference (of that protein) in SS compared with AA MPs — to visually show how abundant proteins were distributed between the 2 MP populations (see Supplemental Tables 1 and 2; supplemental material available online with this article; https://doi.org/10.1172/jci.insight.120451DS1). To generate data for these plots, we applied liquid chromatography–tandem MS (LC-MS/MS) analysis on tryptic digests, and quantified peptides and proteins from each sample by high-resolution survey scan MS1 intensity values. For example, at t = 0 this method allowed us to quantify 905 proteins across AA and SS mouse samples; 165 of these proteins were significantly more abundant (≥1.5-fold value and P ≤ 0.05) in the SS mouse proteome. Among the upregulated proteins in the SS mouse proteome were those associated with oxidative stress, including Hb antioxidant enzymes (described above), membrane structural proteins, mitochondrial proteins, heat shock proteins, and proteins involved in the ubiquitin proteasome machinery. Indeed, this trend was reproduced in additional SS mouse MP studies that included RBC lysate (see below for comparative data). We also included a stress associated posttranslational modification (PTM) analysis to search for PTMs associated with stress, including those associated with Hb oxidative modifications (ubiquitination, phosphorylation, cysteine trioxidation) (13, 24). Representative MS/MS fragmentation spectra are shown in Figure 4, A–C, for each PTM identified in the β subunit of HbS. From these searches, we observed in SS mice (shear stress and circulating) that HbS contained higher levels of irreversible βCys93 oxidation as well as βLys96 and βLys145 ubiquitination compared with HbA from AA mouse MPs. βCys93 oxidation was >2-fold higher in shear stress–generated SS MPs (Figure 5A) and >4-fold higher in circulating SS MPs (Figure 5D). Irreversible oxidation of βCys93 has been shown by our group to be one of the prominent determining features in HbS oxidative instability. Furthermore, we have demonstrated that shielding this amino acid from oxidative challenges improves stability and gelation time (25, 26).
Mass spectrometric analysis of microparticles from sickle mice reveals amino acid posttranslational modifications. MS/MS fragmentation spectra representing (A) y and b fragment ions matched to the Hb tryptic peptide GTFATSELHCDKLHVDPENFR (residues 83–104) containing cysteic acid (48 Da) at βCys93. (B) y and b ions matched to the Hb tryptic peptide GTFATSELHCDKLHVDPENFR containing the ubiquitin diglycine signature modification (114 Da) at βLys96. (C) y and b ions matched to the Hb tryptic peptide VVAGVANALAHKYHK (residues 335133–335145) containing the ubiquitin diglycine signature modification (114 Da) at βLys145.
Representations of amino acid posttranslational modifications reveal significant changes in both shear stress and circulating microparticles. MS/MS fragmentation spectra were used to search for posttranslational modifications (PTMs) previously known to be associated with Hb oxidative stress. (A–F) Relative ion current intensity fold changes corresponding to each Hb amino acid–specific PTM from AA and SS mouse shear stress and circulating microparticles (n = 3); measurements were determined by Hb peptide MS1 chromatogram intensities for each PTM. All peptide-spectrum matches were obtained using a strict 1% protein FDR. (G) Ubiquitinated proteins in AA and SS RBC lysates from 3 sets of mice were immunoprecipitated by protein G agarose beads using anti-ubiquitin antibody. (H) Ubiquitin bound Hb complex formation was analyzed using anti-Hbβ antibody. (I) Proteins present in the eluted immunoprecipitate were also resolved by SDS-PAGE and stained with Coomassie blue. Arrows represent Hbβ subunit. Bars represent average mean value; each dot in the bars represents an individual data point; and vertical error bars represent SEM. Student’s t test, 2-tailed, *P < 0.05 (n = 3).
A remarkable finding in our PTM search was the discovery of ubiquitination at βLys96 and βLys145 (Figure 5, B, C, E, and F). To the best of our knowledge, this is the first report showing ubiquitination of HbS possibly due to accumulation of oxidatively damaged Hb molecules in RBCs/MPs. In addition to mass spectrometric identification, we were also able to capture ubiquitinated Hb within sickle RBCs following inhibition of the UPS and deubiquitinating enzymes (DUBs) by MG132 and N-ethylmalemide (NEM), respectively. Specifically, we employed an orthogonal co-immunoprecipitation (co-IP) assay using an anti-ubiquitin antibody (Figure 5, G and H) to pull down ubiquitin-protein complexes. The immunoblot using an anti-Hbβ antibody (Figure 5H) and Coomassie staining of SDS-PAGE gel (Figure 5I) of eluted ubiquitin-protein complexes from protein G agarose show higher levels of Hb monomers and dimers (indicated by black arrows) in SS mouse RBCs, confirming our results obtained from proteomic analysis. Taken together, our results suggest a relationship between oxidation of βCys93 and the ubiquitination of βLys96 and βLys145 and the possibility of proteasomal inhibition resulting from redox imbalance within sickle RBCs.
Ferryl HbS forms a complex through a covalent attachment to RBC ghost membranes. RBC band 3 proteins have been shown to have increased tyrosine phosphorylation in patients with hemoglobinopathies including SCD and are also known to bind with oxidized forms of Hb to form complex (27–29). We therefore analyzed mouse RBC-derived MPs for possible band 3-Hb association by co-IP assay using a specific band 3 antibody. To investigate the extent of binding with different Hb oxidation intermediates and consequent RBC membrane alteration, we examined the reactivity of ferryl Hb and other redox forms (prepared by the reaction of ferric Hb with H2O2) toward human RBC ghost membranes. Figure 6A shows the absorbance spectra of freshly prepared HbA oxidation intermediates used in these experiments. Using ghost RBC membranes that were treated with different Hb redox states (Fe2+, Fe3+, and Fe4+), we determined Hb intermediate binding to the RBC membrane by a similar co-IP assay (as done before with MPs) using an anti–band 3 antibody. Probing with an antibody against Hb α chain following transfer of eluted proteins from immunoprecipitated band 3 to nitrocellulose membrane revealed binding of Hb with band 3 proteins. As shown in Figure 6B, ferrous and ferric Hb exposure did not cause any complex formation relative to untreated ghost membranes. However, an increased complex formation with Hb was seen in the band 3 eluates from membranes treated with ferryl protein (lane 4, Figure 6B). Proteins eluted from band 3 immunoprecipitates were then resolved on SDS-PAGE. Coomassie staining of the immunoprecipitated band 3 eluates also revealed a high degree of complex formation by ferryl Hb (Figure 6C), as also seen by Western blotting. For quantitation of band intensities, densitometric image analysis was performed (Figure 6D) from a chosen area in the gel (red box) where significant band 3 accumulation was also noted (see Figure 6B, upper panel). Relative band intensities from the 120-kDa region (red box) show a significant increase in complex formation by ferryl Hb (Figure 6D). To identify other proteins, present in the band 3–Hb complex, we analyzed the eluted band 3 immunoprecipitates by MS. Proteomic analysis of bands in the SDS-PAGE gel revealed complex formation with several RBC membrane proteins and Hb subunits. Protein complexes extracted from ghost RBC membrane (treated with different Hb redox forms, specifically the ferryl form) contained several membrane-associated proteins, including spectrin, ankyrin, Hb (both α and β subunits), and the band 3 anion transport protein (Figure 6C). More quantitative analysis is currently underway to fully analyze the nature of interactions between Hb and the RBC proteins.
Hemoglobin oxidation promotes complex formation with band 3. Co-IP of band 3 was done and probed with anti-Hb antibody. (A) The absorbance spectra for the ferrous, ferric, and ferryl Hbs used in experiments. (B) Band 3-Hb complex formation in RBC ghost membrane was analyzed following in vitro incubation with different Hb oxidation states using a co-IP assay and immunoblotted using anti–band 3 and anti-Hb antibodies (lower panel). Upper panel: 90-kDa bands show equal band 3 loading; lower panel: Hb binding developed with anti-Hb antibody. Upper panel: 120-kDa bands indicate high molecular complex with band 3. (C) Eluted proteins from band 3 immunoprecipitates from RBC ghost membranes treated with or without Hb of different oxidation states were resolved by SDS-PAGE, followed by staining with Coomassie blue. The gel bands were further analyzed by LC-MS. Higher levels of membrane protein complexes were found in ferryl Hb–treated RBC ghost membranes (some of the major complexed proteins with Hb α or β subunits include [1] spectrin α; [2] spectrin β, spectrin α, Hbβ, band 3 anion transport protein, Hbα, ankyrin 1; [3] spectrin β isoform A, Hbβ, band 3 anion transport protein, Hbα, ankyrin 1; [4] band 3 anion transport protein, ankyrin 1; [5] erythrocyte membrane protein band 4.2, Hbβ subunit, band 3 anion transport protein, Hbα subunit; [6] Hbβ, and band 3 anion transport protein). All proteins were searched using Mascot and listed in order of Mascot score. (D) Plot representing relative band intensities measured from a specific area of Coomassie-stained gel (120-kDa region, denoted by the red box in C). The values in the graph represent average mean value of 3 independent observations, and each dot in the bars represents individual data points. Vertical error bars represent SEM. Student’s t test, 2-tailed, *P < 0.05 vs. control (n = 3).
MPs from SS mice influence vascular integrity and mitochondrial function. RBC-derived MPs from SCD patients carry a significant portion of heme and cell-free Hb that are delivered to vascular endothelial cells, causing oxidative stress, apoptosis, and vaso-occlusion (3). To investigate the interactions and associated toxicities of shear stress RBC MPs from Townes-SS versus -AA mice in human vascular endothelial cells, we used HUVECs that were exposed to RBC-derived MPs for varying periods of time (up to 12 hours). MPs are known to adhere efficiently to endothelial cells by altering expression of adhesion molecules (3, 15). We first monitored the expression of heme oxygenase–1 (HO-1) in HUVECs as an indicator of Hb cellular uptake of Hb or heme from MPs. Coincubation of SS MPs for 12 hours caused a significant rise in HO-1 level in HUVECs compared with AA MPs (Figure 7, A and B). Next, we sought to observe any changes in vascular endothelial membrane integrity following exposure to RBC-derived MPs by monitoring the permeability of high-molecular-weight dextran using Transwell inserts and by fluorescence microscopy. We first assessed the loss of endothelial monolayer integrity by monitoring the passage of FITC-conjugated dextran (40 kDa). Following 12 hours of incubation, Townes-SS MPs caused an almost 2-fold increase in dextran passage compared with corresponding AA MPs, which suggests a loss of monolayer integrity of HUVECs (Figure 7C). Fluorescence microscopy also revealed changes in the endothelial membrane adherens junctions, as indicated by a significantly altered pattern of the endothelial membrane–specific protein VE-cadherin following exposure to SS MPs for 12 hours (Figure 7D, right panel). To assess the loss of cell viability and apoptotic activation in MP-treated HUVECs, we determined the number of apoptotic cells by automated cell counting using annexin V–propidium iodide dual staining. We found a significantly higher number of apoptotic cells in SS MP–treated HUVECs compared with untreated cells (Figure 7E). However, AA MPs showed only a marginal increase in apoptotic cells relative to untreated control.
Townes-SS RBC–derived microparticles promote toxicity in human endothelial cells. (A) Oxidative toxicity in human umbilical vein endothelial cells (HUVECs) was assessed by expression of HO-1 protein. (B) Relative band intensity ratio representing expression of HO-1 normalized to corresponding β-actin level was measured using Bio-Rad Image Lab software (n = 4) (C) Loss of monolayer integrity in HUVECs exposed to Townes-AA or -SS RBC MPs for 12 hours, measured by passage of FITC-dextran through Transwell membranes (n = 4). (D) Representative fluorescence microscopic images of HUVEC endothelial membrane stained with anti–VE-cadherin (green) showing disruption of membrane integrity by SS MP treatment for 12 hours. (E) Number of apoptotic cells as quantified in HUVEC culture following 12 hours of incubation with SS or AA MPs by cell counter using annexin V and propidium iodide (n = 6). (F and G) Representative plots showing oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) profiles in HUVECs obtained from extracellular flux analyzer following coincubation with either media (Control), Townes-AA MPs, or Townes-SS MPs for 12 hours. Data points represent average OCR/ECAR values of 6 similar wells. Following incubation with MPs, HUVEC were subjected to sequential automated injections of the ATP synthase blocker oligomycin (Oligo), oxidative phosphorylation uncoupler carbonyl cyanide 4-(trifluoromethoxy) phenylhydrazone (FCCP), and a cocktail of the mitochondrial respiration inhibitors rotenone and antimycin A (AA) to obtain the full OCR profile. For ECAR profile, a sequential injections of glucose, oligomycin (Oligo), 2-deoxy-d-glucose (2DG) were made. (H) Average basal OCR and (I) mitochondrial reserve capacity were calculated from 4 separate OCR plots (n = 4). #P < 0.05 vs. control. Upper horizontal line in box plots represent 75th percentile, lower horizontal line in represent 25th percentile, horizontal line within box represents mean value. Vertical error bars represent 95% confidence interval. Student’s t test, 2-tailed, *P < 0.05.
Since endothelial cells are dependent primarily on glycolytic energy production and partially on mitochondrial oxidative phosphorylation; we employed an extracellular flux analyzer (XF assay) to assess any impairment in energy metabolism. We monitored mitochondrial respiration and glycolytic activity in real time within AA and SS MP–treated HUVECs by measuring the mitochondrial oxygen consumption rate (OCR) and the extracellular acidification rate (ECAR), respectively. Representative OCR and ECAR plots are shown in Figure 7, F and G. Calculations of bioenergetic parameters from average OCR changes data did not reveal any alteration in basal mitochondrial OCR following MP treatments, when baseline respiration was corrected for any residual nonmitochondrial oxygen consumption (OCR after addition of rotenone/antimycin A) (Figure 7H). Interestingly, mitochondrial spare respiratory capacity or reserve capacity was marginally affected in HUVECs exposed to SS MPs, indicating compromised ability of the cells to respond to increased energy demand (Figure 7I). However, endothelial glycolytic capacity, which is the maximum ECAR achieved following oligomycin injection, was mostly unaffected by any of the MPs (data not shown).
HU treatment reduces Hb posttranslational modifications. We repeated the same proteomic comparative approach (see Figure 3, B and C) on MPs derived from blood and RBC lysates with a new set of AA and SS mice (n = 3). In addition, we also treated SS mice with the anti-sickling agent HU for 10 days and analyzed MPs from HU-treated versus untreated SS mice. Expressing human HbS in SS mice reproducibly induced oxidative stress; this can be seen by comparing Figure 8A with the volcano plots represented in Figure 3. A total of 855 proteins across both SS MP and AA MP samples were identified; 276 of these proteins were significantly more abundant (≥1.5-fold value and P ≤ 0.05) in the SS mouse proteome. Once again, a majority of these abundant proteins were clearly associated with oxidative stress, including antioxidant enzymes, membrane structural proteins, heat shock proteins, and the 26S proteasome, etc. (see Supplemental Table 3). As seen for Figure 3, a substantial increase in the abundance of particular mitochondrial proteins in SS relative to AA mouse MPs was also shown in the proteome-wide quantification volcano plot in Figure 8A. The presence of relatively abundant mitochondrial proteins in SS RBC/MP lysates is surprising. However, recent literature shows that excessive ROS in SCD are associated with abnormal mitochondrial retention (30, 31). The greater abundance of mitochondrial proteins and some antioxidants in SS MPs may also originate from immature RBCs (reticulocytes), as blood of Townes-SS mice contains a substantial population of reticulocytes (32). We recently reported that Townes-SS mice have 37%–58% reticulocytes as a percentage of total RBCs (33). As a follow-up, we performed an additional proteomic comparison of AA and SS samples for the RBC lysate (see Figure 8, A and B). There are some important differences between the MP and RBC lysate proteomes (see Supplemental Table 4). First, the SS RBC lysate contains substantially fewer mitochondrial proteins than the SS MP, which suggests that mitochondrial retention may be localized to MPs or alternatively mitochondrial proteins are enriched (along with other organellar proteins associated with reticulocytes) in the MP preparation. Second, the 5 enzymes listed in Figure 3A (glutathione peroxidase 1, peroxiredoxin 6, thioredoxin, catalase, and SOD) were at comparable levels in AA and SS RBC lysates, which contrasts with the MP proteome. Upregulated proteins in the RBC lysate proteome consists primarily of cytosolic proteins including ribosomal proteins, translational proteins, cytoskeletal proteins, metabolic proteins, heat shock proteins, and ubiquitin proteasome machinery proteins. Most of these proteins are also seen in the MP proteome data. Interestingly, antioxidant proteins seen to be upregulated in the RBC lysate are primarily involved in iron homeostasis, including serotransferrin, glutaredoxin-3, and transferrin-like protein. We also checked the levels of some important glycolytic and MAPK enzymes in the AA and SS RBC lysates by Western blotting. Specifically, the level of ERK1/2 enzyme, but not glycolytic enzymes such as GAPDH, was found to be upregulated in the SS RBCs (data not shown).
Hydroxyurea treatment reduces posttranslational modifications in microparticles. A second proteomic comparative analysis including MPs derived from the blood of a set of AA, SS, and hydroxyurea-treated (HU-treated) SS mice (n = 3). (A) Volcano plots represent average relative fold differences determined by plotting P values (–log10) for each protein against the calculated fold change (log2) difference (of that protein) in SS relative to AA microparticle peptide MS1 chromatogram intensities that were combined for each protein into protein-level data. (B) Volcano plots represent average relative fold differences determined by plotting P values (–log10) for each protein against the calculated fold change (log2) difference (of that protein) in SS relative to AA RBC lysate peptide MS1 chromatogram intensities that were combined for each protein into protein-level data. (C) Volcano plots represent average relative fold differences determined by plotting P values (–log10) for each protein against the calculated fold change (log2) difference (of that protein) in HU-treated SS relative to SS microparticle peptide MS1 chromatogram intensities that were combined for each protein into protein-level data. All peptide-spectrum matches were obtained using a strict 1% protein FDR. P values were generated by applying a t test statistic to log2-transformed fold change values for each mouse biological condition. (D–F) Relative ion current intensity fold changes corresponding to each Hb amino acid–specific PTM from HU-treated and untreated SS mouse shear stress MPs (n = 3); measurements were determined by Hb peptide MS1 chromatogram intensities for each PTM. All peptide-spectrum matches were obtained using a strict 1% protein FDR, and P values were generated by applying a t test statistic for each mouse biological condition. (G) Representative Western blot showing comparative Hb binding in immunoprecipitated band 3 elute of RBC MPs from AA, SS, and SS treated with HU. Top panel: equal loading in band 3 protein input. Lower panel: presence of Hbα protein in the band 3 immunoprecipitate elute. (H) Average band intensities of Hb in band 3 immunoprecipitate from AA, SS, and SS + HU MPs were measured using Bio-Rad Image Lab software and expressed as relative density following normalization with corresponding band 3 protein bands. Bars represent average mean value; each dot in the bars represents an individual data point; and vertical error bars represent SEM. Student’s t test, 2-tailed, *P < 0.05 (n = 3).
In contrast to the volcano plots represented in Figure 8, A and B, the volcano plot in Figure 8C representing the proteomic comparison of SS and SS HU samples indicates that most proteins were similar in abundance, with data points clustered in the center of the plot, which represents 0-fold change (see Supplemental Table 5). While protein levels associated with oxidative stress were similar in HU-treated and untreated SS samples, there were clear differences in Hb PTMs which is represented by the graphs in Figure 8, D–F. Moreover, Hb PTM fold change values (Figure 8, D–F) representing βCys93 oxidation and βLys96 and βLys145 ubiquitination, were lower for HU-treated mice, suggesting that HU did provide antioxidative protection. To explore the effects of HU treatment on the interaction between RBC membrane-bound band 3 and Hb, we conducted a co-IP assay using RBC-derived MPs from Townes- SS mice treated with or without HU. We compared band 3 immunoprecipitates from shear stress MPs obtained from AA mice, SS mice, and SS mice treated with HU (Figure 8G). Relative intensities of Hb bands in band 3 eluates showed a significant increase in Hb level in band 3 immunoprecipitate of SS MPs over corresponding AA MPs following normalization with band 3 level (Figure 8H). In this experiment, however, the HU treatment group showed a marginally lower Hb level associated with band 3 than corresponding SS MPs.
HU antioxidative protection involves the reduction of ferrylhemoglobin S through S-nitrosylation. In addition to increasing fetal Hb (HbF) levels, HU may also serve as an antioxidant (34, 35). Therefore, we next investigated the effect of HU on ferryl Hb. Figure 9A shows spectral changes reflecting H2O2-induced Hb oxidation and capturing of the ferryl species as a sulfHb intermediate upon sodium sulfide (Na2S) addition (the resultant sulfHb absorbs strongly at 620 nm). At a 1:2.5 (heme/H2O2) ratio, there was a clear reduction in the 620-nm absorption peak after addition of HU, and ferryl/sulfHb levels were considerably reduced, from 27 μm to 17 μm. The above trend is further exemplified in Figure 9B, whereby the formation of ferryl Hb/sulfHb was increased in a dose-dependent manner with the addition of H2O2. Furthermore, by adding HU, the formation of these highly reactive forms of Hb were clearly suppressed at all H2O2/heme ratios. Overall, these findings are consistent with prior reports indicating that HU generates NO as part of its rapid decomposition and in the presence of Hb causes S-nitrosylation of Cys93 (36). Indeed, MS analysis of the peptide that contained βCys93 (residues 83–104) confirmed the formation of S-nitrosylated Hb (SNO) in the presence of HU, as shown in Figure 9C. This may mechanistically explain the antioxidative properties of HU (34, 35) and is also consistent with recent reports showing that reversible cysteine oxidative posttranslational modifications such as S-nitrosylation play a role in regulating protein structure and function (37).
Hydroxyurea reduces ferryl heme and shields βCy93 by a process of S-nitrosylation. Effects of HU on the levels of ferryl Hb (made with the addition of 150 μM H2O2). (A) Overlaid sulfHb spectra (absorption at 620 nm) of HbS (60 μM) treated (dashed line) and non-treated with HU (240 μM) (solid line). (B) Amounts of sulfHb produced at various ratios of H2O2 to Hb; nontreated HbS (solid black) and HU-treated (pattern). (C) MS/MS fragmentation spectrum representing the y and b ions matched to the modified tryptic peptide GTFATSELHCDKLHVDPENFR (residues 83–104) (residues 82–104) from Hb incubated with HU; this peptide contains the diglycine signature modification (at βLys96) associated with ubiquitination and S-nitrosylation (at βCys93). Bars represent average mean value; each dot in the bars represents an individual data point, and vertical error bars represent SEM. Student’s t test, 2-tailed, *P < 0.05 HbS vs. corresponding HbS + HU (n = 3).
SCD RBCs are subjected to constant endogenous and exogenous oxidative stresses, which in turn increase hemolysis and contribute to vasculopathies, one of the hallmarks of this disease (5). Moreover, recent studies on SCD patient blood samples have revealed an increase in sickle RBCs retaining mitochondria when compared with samples from healthy individuals. Using an accompanying experimental SCD mouse model, the same report also indicated that excessive levels of ROS were associated with abnormal mitochondrial retention (30, 31).
Cumulative internal oxidative stress and a decrease in antioxidant defenses are coupled with increasing Hb nonenzymatic oxidation (autoxidation) (38) and pseudoperoxidase activities in the presence of oxidants (such as H2O2) in SCD (39). In fact, ferryl Hb and the radical byproducts of this reaction are capable of interacting with other biological and structural proteins within RBCs. Ferryl HbS has indeed been found to inhibit actin polymerization in malaria-infected HbS RBCs, in spite of the presence of RBC antioxidative enzymes (40). Compared with steady-state conditions, the occurrence of vaso-occlusive crises in SCD has been shown to be associated with an increase in the levels of both RBC-derived MPs and extracellular Hb in the circulation. The common byproduct resulting from free Hb oxidation and from Hb-laden MPs is heme, which has been shown to initiate inflammatory responses (3, 41).
In the present study, we examined a potential mechanistic link between Hb internal oxidative pathways, membrane alteration, MP formation, and vascular toxicity in a Townes-transgenic SCD mouse model. This model is ideal for these studies because mice live in a controlled environment, possess less genetic variability, and therefore require a small sample size for acquiring statistically significant data. We monitored Hb oxidative changes within MPs over an extended period of time for the following reasons: (a) MPs derived from sickle RBCs have been shown to be important delivery vehicles for Hb and heme (3, 41) and (b) cellular and subcellular entrapment of RBC MPs and internalization by cells have been observed to modulate function in a time-, dose-, and temperature-dependent manner (42). Furthermore, the mechanism of Hb/heme loss and time frame by which heme is released from MPs are incompletely characterized.
As shown in Figure 2D, we found high levels of metHb, up to 30%–40% of total Hb in SS MPs at the start of the incubation period, which was then reduced slightly by residual antioxidant enzymes from the mother cells. This agrees with a recent photometric analysis of SS RBC-derived particles (3) but contradicts an earlier reported observation that found that Hb existed predominantly in the ferrous form in MP-derived samples from outdated normal blood (43). HRAM-MS analysis of the proteome at 0 and 30 hours showed a dramatic reduction in antioxidant protein levels within RBC-derived SS MPs at the end of the observation period. Catalase, SOD, glutathione peroxidase 1, and peroxiredoxin 6 were among the proteins found to be significantly impaired. The depletion of this cytosolic reductive capacity left these Hb oxidative reactions unregulated and consequently resulted in perpetuating oxidative changes and the formation of damaging ferryl species. These self-inflected oxidative changes (including the formation of the ferryl heme and its radical result in Hbβ alteration) can be seen in our HPLC profiles of Hb in the SS MPs. In addition to this work showing MP proteomic differences with respect to antioxidant enzymes (which reflects change in pathophysiology of HbS mice), recent metabolic profiling of normal and SCD human RBC samples has also revealed the impact of HbS on the metabolome. Specifically, Darghouth et al. recently reported that SCD patients exhibit changes to oxidative damage control systems; in SCD RBCs, glutathione and oxidized glutathione levels were decreased, whereas the concentrations of their precursors as well as ascorbate metabolism intermediates were increased (44).
The mouse MP proteomic landscape analysis from 2 separate comparative studies confirmed that SS mice experience HbS-induced oxidative stress. A large number of proteins previously reported to be associated with oxidative stress were significantly upregulated in the SS MP proteome (relative to the AA MPs). In particular, we observed a substantial increase in mitochondrial proteins. This supports a recent study that linked oxidative stress within SCD RBCs with the retention of mitochondria (30). However, Townes-SS mouse blood has been reported to contain 50%–70% more reticulocytes and immature nucleated RBCs (32) compared with AA controls; the source of mitochondrial proteins (and other organellar proteins) in our mass spectrometric analysis of the mouse proteome (see Supplemental Tables 1–5) could therefore be partially due to the presence of reticulocytes. In addition to changes in the levels of antioxidant enzymes, we also observed increases in translation factors, molecular chaperones, UPS proteins, and those associated with the 20S proteasome — all of which are consistently associated with oxidative stress (45–47).
Additionally, HbS was significantly more oxidized at the hotspot residue βCys93 relative to HbA from AA mice. This further supports the oxidation kinetics data (described herein) indicating that SS MPs contain higher levels of ROS. Generally, when naturally occurring mutant Hbs (including HbS) are chemically challenged with H2O2, extensive globin chain crosslinking and irreversible modification of key β subunit amino acids (known as oxidation hotspots) occurs (13, 48). These amino acids (βHis146, β Tyr145, βCys93, βTrp37, and βPro36) are located in proximity to the α/β interface, which happens to be the point of contact with the antioxidant Hp (8, 49). This is consistent with our earlier observations that βCys93 and other hotspot residues can be considered as a reliable reporter for oxidative modifications and degradation for the Hb molecule (13, 25).
We also identified HbS PTMs such as ubiquitination at K96 and K145. These ubiquitinated sites in HbS were higher in all SS MPs examined in this report (see Supplemental Tables 1–3 and 6). Ubiquitination is an ATP-dependent modification requiring the UPS machinery (selective proteolytic system in eukaryotic systems), which has recently been reported to be functionally active in mature normal RBCs (47, 50). Interestingly, ubiquitinated protein targeting by the UPS has also been found to be associated with protein oxidation and subsequent aggregation (24). Our method detects the diglycine moiety that is associated with ubiquitination but does not differentiate between mono- and polyubiquitination (51). However, orthogonal co-IP experiments following inhibition of the proteasomal system and deubiquitinase enzymes present in RBCs by MG132 and NEM, respectively, confirmed the existence of ubiquitinated forms of Hb, potentially signaling an accumulation of modified Hb that can lead to its degradation. Further, Townes-SS mice have a population of immature RBCs, so it would not be surprising to see an accumulation of many of newly synthesized ubiquitinated Hbs (33, 52). As we consistently found higher levels of Hb ubiquitination and Hb oxidation in all SS RBC-derived MPs, the most likely possibility is impairment of the proteasomal machinery in SCD due to a redox imbalance leading to a buildup of ubiquitinated (mono-, di-, or poly-) Hb. By suggesting a link between HbS oxidation and ubiquitination, our MP proteome data provide insight into a potential mechanism of removing toxic HbS (during oxidative stress). Our data also reveal a possible link between ubiquitination and the DAMP molecular system, since it has recently been shown that the TLR4 signaling pathways are also regulated by the ubiquitin-proteasome system (53).
Hb oxidation products (including hemichromes) have high affinity toward the cytoplasmic domain of band 3 and are reported to mediate oxidative crosslinking through disulfide bonds (28, 29, 54). Band 3 clustering has been shown to be associated with blebbing and MP generation, which are important characteristics of SCD and β-thalassemias (55, 56). In this study, we used purified ferryl Hb (by reacting H2O2 with metHb and rapidly removing the oxidant by chromatography) in a medium of ghost cells (57). We also avoided the use of phenylhydrazine, a commonly utilized oxidant known to generate redox-inactive hemichromes, in which the heme iron is hexa-coordinately bound to the protein (58). Using specific antibodies against band 3 and Hb, we were able to demonstrate that ferryl Hb is more effective in producing complexes with band 3 than both the ferric and ferrous forms of Hb. Co-IP followed by MS confirmed the presence of membrane-associated proteins in the medium, to which ferryl Hb was added. This is consistent with recent experiments in which ghost cells derived from normal human RBCs were used (57). Taken together, these experiments showed that ferryl Hb (but not hemichromes) induces more membrane complexes and that approximately 50% of this binding involves reactive sulfhydryl groups, likely from βCys93 (57).
Our experiments with endothelial cells further indicated that SS MP toxicities are related to their distinct oxidative profile. Camus et al. previously showed heme accumulation and Hb within endothelial cells (following adhesion of sickle RBC–derived MPs) resulted in rapid generation of intracellular ROS and activation of apoptosis (3). Hb accumulation within tubulointerstitial or intraglomerular capillaries has also been shown by the same group in human SCD renal biopsies (16). Selective passage of blood or plasma components into the adjacent tissues is well controlled by vascular endothelium acting as a dynamic barrier. Various stress conditions including inflammatory mediators are known to damage vascular endothelial integrity (59). We have previously shown that HbS (especially in its oxidized form) can damage endothelial monolayer integrity more effectively than HbA (60). Our results showing a loss of monolayer integrity by SS MPs may be attributable to their high HbS content coupled with higher rates of oxidation of HbS over HbA, and the formation of more persistent and damaging oxidized species that can target other biological molecules (13). Our data establish a link between the loss of endothelial monolayer integrity with concomitant apoptosis and induction of HO-1 expression by SS MPs. We therefore measured HO-1 as secondary evidence of Hb- (and heme-) mediated toxicity in HUVECs. Higher HO-1 expression in SS MP-treated HUVECs is indicative of increased Hb oxidation and catabolism, consistent with those previous reports (3). Moreover, our results also indicated an impairment in mitochondrial bioenergetics, noticeable specifically under an FCCP-induced uncoupled state. The loss in mitochondrial reserve capacity in endothelial cells by SS MPs indicates a failure of the mitochondrial population to respire to their maximum possible rate during high energetic demand. We and others have previously shown that HO-1 expression with its localization into mitochondria leads to a compromised bioenergetic state under the influence of oxidized Hb or heme (61, 62). Therefore, it is possible that a similar mechanism is also operational in our MP-based model. However, the major metabolic pathway in endothelial cells, i.e., glycolysis, remains unaltered by MP exposure. It was previously demonstrated that erythrocyte MPs can trigger rapid vaso-occlusions in tissues sensitive to ischemic injury (16). Our present observations with HUVECs exposed to SS MPs suggest that HbS-rich MPs may cause significant pathophysiological impairment as seen in SCD and other hemolytic disorders, including decreased vasodilation and massive vaso-occlusion, by damaging vascular integrity.
To investigate the impact of HU treatment on oxidative pathways of Hb in both RBCs and MPs, we analyzed blood from untreated mice and those treated with HU; overall, the abundance levels of most proteins were similar for both mouse populations. However, we observed reductions in HbS βCys93 and ubiquitination of βLys96 as well as βLys145 relative to untreated SS mice, which suggests an additional antioxidant benefit from HU (63). This is also in keeping with recent clinical trials on HU treatment of SCD children, in which children were reported to show decreases in plasma MPs derived from RBCs and platelets (64).
In summary, Hb transformation to higher oxidative forms was markedly increased in MPs generated from SCD mice in a pattern similar to that of their parent RBCs (see the scheme in Figure 10). Ferryl Hb (once formed) manifested several oxidative changes, including irreversible oxidation of βCys93 and ubiquitination of βLys96 and βLys145. Ferryl Hb also oxidatively targeted band 3, which resulted in band 3–mediated complex formation (with Hb and other membrane proteins) and activation of the UPS pathway. HU appeared to have an antioxidant effect, as it potentially minimized the consequences of these processes through S-nitrosylation of βCys93. When MPs were incubated with endothelial cells, this led to mitochondrial dysfunction and eventually apoptotic cell death. Taken together, these mechanistic results suggest that Hb oxidative pathways drive oxidative changes within SCD RBCs and similarly in RBC-derived MPs and that antioxidative interventions may slow down and/or prevent Hb-oxidative side reactions in SCD.
Proposed erythrocyte internal oxidative changes that trigger membrane alternations and microparticle formation. Oxidative reactions within RBCs include the following pathways: (1) Ferrous Hb (Fe2+) undergoes spontaneous oxidation (autoxidation) to form ferric Hb (Fe3+), and in the presence of H2O2 ferryl Hb (Fe4+) is formed when antioxidative mechanisms are compromised. Ferryl Hb undergoes oxidative changes including irreversible oxidation of βCys93 and ubiquitination of some lysine residues. Ferryl Hb can oxidatively target band 3, leading to complex formation and microparticle formation (2) or denaturation and proteasome degradation (3). Some ferryl Hbs revert back to ferric by a process of autoreduction (4). Hydroxyurea acts as an antioxidant by forming SNO-Hb at βCys93 by a process of S-nitrosylation, thereby minimizing the consequences of these processes (adapted with modification from ref. 23).
Sickle cell mouse model and treatment with HU. HbSS-Townes mice were created by knocking in human α and βS globins into the sites where murine α and β globins were knocked out. HbSS-Townes mice have severe anemia and an RBC half-life of 2.5 days. HbAA-Townes control mice (RBC half-life, 16 days) were created by replacing βS with βA. (65). Heparinized blood was obtained from Townes mice (total 21 Townes-AA and Townes-21 SS). In some experiments, Townes-SS mice were treated with HU for 10 days with a diet containing 100 mg/kg HU in water/methylcellulose, while control animals had water/methylcellulose vehicle only. Both groups drank the same volume of water over the 10 days. Isoelectric focusing analysis of different mouse blood samples was carried out using RBC lysates. See Supplemental Methods for details.
Preparation of MPs from mouse blood. For the majority of experiments, MPs were generated by shear stress from RBCs (18). Heparinized whole blood was used for the preparation of RBC MPs. Shear stress MPs were generated by passing PBS-washed RBCs rapidly through a 25G needle. A detail description of RBC-derived and circulating MP preparation is provided in Supplemental Methods.
Flow cytometric and electron microscopic analysis of RBC MPs. RBC-derived MPs were counted by flow cytometry and visualized through cryogenic transmission electron microscopy (cryo-TEM). For details, see Supplemental Methods.
Autoxidation experiments. Quantification and determination of the oxidation state within MPs were achieved by using a Nanodrop 1000 spectrophotometer together with conventional spectrophotometers. Multicomponent analysis was used to calculate ferrous (oxy-), met-, and ferryl Hb based on the extinction coefficients of each species (22). For further details and biochemical analysis of MPs, see Supplemental Methods.
Reverse-phase HPLC analyses of Hb oxidative changes within MP oxidation. Reverse-phase HPLC analyses of MPs were performed on a Zorbax 300 SB C3 column (4.6 × 250 mm) using a Waters HPLC system as described earlier (13). For details, see Supplemental Methods.
Preparation of ferric and ferryl Hbs. Ferric (met) and ferryl Hb were generated as previously reported (13, 22). See Supplemental Methods for details.
Hydrogen peroxide–mediated oxidation of Hb and the effects of HU. Dose-dependent H2O2-induced ferryl Hb species formation was evaluated with and without HU following previously described methods (22). For verification of the ferryl intermediate, 2 mM Na2S was added immediately to derivatize the ferryl heme into sulfHb (66). See Supplemental Methods for details.
Western blotting and co-IP. Immunoblotting was done as previously reported (62). A detail description is provided in Supplement Methods.
Vascular endothelial cell culture and treatments. Cryopreserved HUVECs were cultured using M200 media according to the supplier’s protocol (Thermo Fisher Scientific).
The cells were exposed to different RBC-derived MPs isolated from Townes mouse blood (1,000 MPs/μl) for varying periods of time up to 12 hours. See Supplement Methods for details.
Assessment of endothelial damage by Transwell assay and apoptotic activation. Loss of endothelial monolayer integrity was studied by monitoring passage of FITC-labeled dextran (40 kDa) through an HUVEC monolayer grown on collagen-coated PTFE-Transwell membrane inserts (Corning Inc.) as described previously (60). HUVEC monolayer integrity was also observed by fluorescence microscopy using an antibody against endothelium-specific VE-cadherin. The percent apoptotic cell population in MP-challenged HUVECs was determined by a Nexcelom Automated Cell Counter (Nexcelom Bioscience). More details are provided in the Supplemental Methods.
Mitochondrial bioenergetic and glycolytic flux measurements with Seahorse analyzer. Endothelial OCR and ECAR were measured to assess mitochondrial respiration and glycolysis, respectively, and plotted using an Agilent Seahorse XF24 extracellular flux analyzer, as per the manufacturer’s instructions and as described previously (13, 60). Various cellular bioenergetic parameters were calculated from average rate data obtained from individual wells as described previously (67, 68). See Supplemental Methods for more details.
LC-MS analysis of band 3 co-IP. Proteins in band 3 immunoprecipitates resolved by SDS-PAGE were subjected to MS analysis using LC-MS. Gel slices were excised, digested, and then analyzed by MS. See Supplemental Methods for more details.
Proteomic analysis of MPs. Prior to MS analysis, the total protein concentration of all RBC-derived MPs was determined using a standard BCA assay. Afterward, samples were tryptically digested, desalted, and analyzed by MS as previously described (69). Quantitative data processing and visualization were performed using both Protalizer DDA software (Vulcan Analytical) version 1.1.2418 and X! Tandem Piledriver search engine version 2015.04.01.1 (70, 71). See Supplemental Methods for further details.
Statistics. See Supplemental Methods for a detailed description of statistical analysis.
Study approval. All mice were maintained at the University of Minnesota Medical School. All animal studies were approved by the University of Minnesota Institutional Animal Care and Use Committee.
SJ and AIA conceived and designed the study. SJ and MBS performed a majority of the experiments and data analysis. FM, TK, and WH performed other biochemical experiments and data analysis. SDP and IT performed electron microscopic studies and flow cytometry. MRH assisted in proteomic data analysis. GMV and JDB contributed to the overall design of animal experiments and manuscript editing. JS contributed to the development of the MP preparation protocol and the design of physical characterization studies of MPs. SJ, MBS, and AIA drafted the manuscript. All authors read and approved the final manuscript.
This work was supported by the NIH/NHLBI under grants HL110900 (to AIA) and by the US Food and Drug Administration (MODSCI 2012 to AIA). JDB and GMV receive research funding from the NIH (R01HL114567).
Address correspondence to: Abdu I. Alayash, Laboratory of Biochemistry and Vascular Biology, Center for Biologics Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Avenue, Building 52/72, Room 4106, Silver Spring, Maryland 20993, USA. Phone: 240.402.9350; Email: abdu.alayash@fda.hhs.gov.
Conflict of interest: JDB and GMV receive research funding from CSL Behring.
License: Copyright 2018, American Society for Clinical Investigation.
Reference information: JCI Insight. 2018;3(21):e120451. https://doi.org/10.1172/jci.insight.120451.